Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTPJ2SH)

• DTT Name: N-sulphoglucosamine sulphohydrolase (SGSH)
• Synonyms: Sulphamidase; Sulfoglucosamine sulfamidase; HSS
• Gene Name: SGSH
• DTT Type: Clinical trial target; [1]
• BioChemical Class: Sulfur-nitrogen hydrolase
• UniProt ID: SPHM_HUMAN
• TTD ID: T64645
• EC Number: EC 3.10.1.1
• Sequence:
  MSCPVPACCALLLVLGLCRARPRNALLLLADDGGFESGAYNNSAIATPHLDALARRSLLF
  RNAFTSVSSCSPSRASLLTGLPQHQNGMYGLHQDVHHFNSFDKVRSLPLLLSQAGVRTGI
  IGKKHVGPETVYPFDFAYTEENGSVLQVGRNITRIKLLVRKFLQTQDDRPFFLYVAFHDP
  HRCGHSQPQYGTFCEKFGNGESGMGRIPDWTPQAYDPLDVLVPYFVPNTPAARADLAAQY
  TTVGRMDQGVGLVLQELRDAGVLNDTLVIFTSDNGIPFPSGRTNLYWPGTAEPLLVSSPE
  HPKRWGQVSEAYVSLLDLTPTILDWFSIPYPSYAIFGSKTIHLTGRSLLPALEAEPLWAT
  VFGSQSHHEVTMSYPMRSVQHRHFRLVHNLNFKMPFPIDQDFYVSPTFQDLLNRTTAGQP
  TGWYKDLRHYYYRARWELYDRSRDPHETQNLATDPRFAQLLEMLRDQLAKWQWETHDPWV
  CAPDGVLEEKLSPQCQPLHNEL
• Function: Catalyzes a step in lysosomal heparan sulfate degradation.
• KEGG Pathway:
  Glycosaminoglycan degradation (hsa00531)
  Metabolic pathways (hsa01100)
  Lysosome (hsa04142)
• Reactome Pathway: HS-GAG degradation (R-HSA-2024096)

Molecular Interaction Atlas (MIA) of This DTT

4 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LYS-SAF302	DMUQWRD	Mucopolysaccharidosis	5C56.3	Phase 2/3	[2]
HGT-1410	DMHZ4JI	Sanfilippo syndrome	5C56.3Y	Phase 2	[1]
ABO-102	DMFJB35	Mucopolysaccharidosis	5C56.3	Phase 1/2	[3]
SOBI003	DMXNTR7	Sanfilippo syndrome	5C56.3Y	Phase 1/2	[4]

References

• [1] ClinicalTrials.gov (NCT01155778) Safety, Tolerability, Ascending Dose and Dose Frequency Study of rhHNS Via an IDDD in MPS IIIA Patients. U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of Lysogene.
• [3] Clinical pipeline report, company report or official report of Abeona Therapeutics.
• [4] Clinical pipeline report, company report or official report of Swedish Orphan Biovitrum.